Molecularly targeted therapies in head and neck cancers

Otolaryngologia Polska

Volumn 66, Issue 5, 2012, Pages 307-312

  Sawicki, Marek ^a   Szudy, Aneta ^a   Szczyrek, Michał ^a   Krawczyk, Paweł ^a   Klatka, Janusz ^a  

^a Lublin University of Techology   (Poland)

Author keywords

Cetuximab; EGFR; Head and neck cancers; Molecularly targeted therapy; Monoclonal antibodies; VEGFR

Indexed keywords

AFATINIB; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; METHOTREXATE; NINTEDANIB; PANITUMUMAB; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; WANDETANIB; ZALUTUMUMAB;

ADVANCED CANCER; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FLUID RETENTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LYMPH NODE METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE; WEAKNESS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84867103069     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otpol.2012.06.021     Document Type: Article

References (43)

1. A. Hoellein, A. Pickhard, F. von Keitz, S. Schoeffmann, G. Piontek, and M. Rudelius Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck Oncotarget 2 8 2011 599 609
2. http://seer.cancer.gov/csr/1975-2008, reviewed April 15, 2011.
3. A.R. Kreimer, G.M. Clifford, P. Boyle, and S. Franceschi Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review Cancer Epidemiology, Biomarkers & Prevention 14 2005 467 475
4. C.G. Hobbs, J.A. Sterne, M. Bailey, R.S. Heyderman, M.A. Birchall, and S.J. Thomas Human papillomavirus and head and neck cancer: a systematic review and meta-analysis Clinical Otolaryngology 31 2006 259 266
5. L. Licitra, C. Bergamini, A. Mirabile, and R. Granata Targeted therapy in head and neck cancer Current Opinion in Otolaryngology & Head and Neck Surgery 19 2 2011 132 137
6. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer Journal of Clinical Oncology 21 14 2003 2787 2799
7. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology 2 2 2001 127 137
8. R.N. Jorissen, F. Walker, N. Pouliot, T.P. Garrett, C.W. Ward, and A.W. Burgess Epidermal growth factor receptor: mechanisms of activation and signalling Experimental Cell Research 284 1 2003 31 53
9. J. Baselga The EGFR as a target for anticancer therapy - focus on cetuximab European Journal of Cancer 37 Suppl. 4 2001 S16 S22
10. K.K. Ang, B.A. Berkey, X. Tu, H.Z. Zhang, R. Katz, and E.H. Hammond Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Research 62 24 2002 7350 7356
11. R.G. Pomerantz, and J.R. Grandis The role of epidermal growth factor receptor in head and neck squamous cell carcinoma Current Oncology Reports 5 2 2003 140 146
12. A. Dietz, A. Boehm, C. Mozet, G. Wichmann, and A. Giannis Current aspects of targeted therapy in head and neck tumors European Archives of Oto-Rhino-Laryngology 265 Suppl. 2008 S3 S12
13. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biology and Therapy. 2006;5(4):340-342.
14. F. Rivera, A. García-Castaño, N. Vega, M.E. Vega-Villegas, and L. Gutiérrez-Sanz Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial Expert Review of Anticancer Therapy 9 10 2009 1421 1428
15. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: Globocan 2008 International Journal of Cancer 127 2010 2893 2917
16. J.B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, and F. Rolland Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy Journal of Clinical Oncology 25 16 2007 2171 2177
17. B. Burtness, M.A. Goldwasser, W. Flood, B. Mattar, and A.A. Forastiere Eastern Cooperative Oncology Group Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study Journal of Clinical Oncology 23 34 2005 8646 8654
18. R. Mesía, F. Rivera, A. Kawecki, S. Rottey, R. Hitt, and H. Kienzer Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck Annals of Oncology 21 10 2010 1967 1973
19. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncology 11 1 2011 21 28
20. M. Goerner, T.Y. Seiwert, and H. Sudhoff Molecular targeted therapies inhead and neck cancer - an update of recent developments Head & Neck Oncology 2 2010 8
21. J.C. Sok, F.M. Coppelli, S.M. Thomas, M.N. Lango, S. Xi, and J.L. Hunt Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clinical Cancer Research 12 17 2006 5064 5073
22. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn, and P.W. Zoltick Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Research 55 23 1995 5536 5539
23. H. Ge, X. Gong, and C.K. Tang Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis International Journal of Cancer 98 2002 357 361
24. I. Okamoto, L.C. Kenyon, D.R. Emlet, T. Mori, J. Sasaki, and S. Hirosako Expression of constitutively activated EGFRvIII in non-small cell lung cancer Cancer Science 94 2003 50 56
25. N. Sahu, and J.R. Grandis New advances in molecular approaches to head and neck squamous cell carcinoma Anticancer Drugs 22 7 2011 656 664
26. J.P. Machiels, S. Subramanian, A. Ruzsa, G. Repassy, I. Lifirenko, and A. Flygare Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Lancet Oncology 12 4 2011 333 343
27. http://www.genmab.com/Science%20And20Research/ Products%20in%20Development/Zalutumumab.aspx, reviewed January 31, 2011.
28. http://www.cancer.gov/search/resultsclinicaltrials.aspx?protocolsearch/ id8073033, reviewed January 31, 2011.
29. S. Stewart, E. Cohen, L. Licitra, C.M.L. Van Herpen, C. Khorprasert, and D. Soulieres A phase III randomized parallel-group study of gefitinib (Iressa) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck Proceedings of the American Association for Cancer Research 2007 A3522
30. O.O. Abidoye, E.E. Cohen, S.J. Wong, M.F. Kozloff, S.R. Nattam, and K.M. Stenson A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) Journal of Clinical Oncology 24 18 2006 5568
31. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, and L.R. Chirieac BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
32. N. Yamamoto, S. Katakami, T. Atagi, K. Hida, T. Goto, and T. Horai A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib or gefitinib Poster presented at: the Annual Meeting of the American Society of Clinical Oncology 4-8 June 2011 [Abstract 7524]
33. T.Y. Seiwert, J. Fayette, D. Cupissol, J.M. Del Campo, P. Clement, and J. Tourani A randomized, open-label phase II study of afatinib (BIBW 2992) versus cetuximab in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (HNSCC) after failure of platinum-containing therapy with a cross-over for progressing patients The 35th European Society for Medical Oncology (ESMO) 8-12 October 2010 [Abstract 1010PD]
34. M. Agulnik New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) Medical Oncology 2012 10.1007/s12032-012-0159-2
35. N. Ferrara VEGF as a therapeutic target in cancer Oncology 69 Suppl. 3 2005 S11 S16
36. K.M. Cook, and W.D. Figg Angiogenesis inhibitors: current strategies and future prospects CA - A Cancer Journal for Clinicians 60 4 2010 222 243
37. E.E. Cohen, D.W. Davis, T.G. Karrison, T.Y. Seiwert, S.J. Wong, and S. Nattam Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Lancet Oncology 3 2009 247 257
38. C. Elser, L.L. Siu, E. Winquist, M. Agulnik, G.R. Pond, and S.F. Chin Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma Journal of Clinical Oncology 24 2007 3766 3773
39. Q. Zhang, S.M. Thomas, S. Xi, T.E. Smithgall, J.M. Siegfried, and J. Kamens SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells Cancer Research 17 2004 6166 6173
40. D.L. Wheeler, M. Iida, T.J. Kruser, M.M. Nechrebecki, E.F. Dunn, and E.A. Armstrong Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab Cancer Biology & Therapy 8 2009 696 703
41. F.M. Johnson, B. Saigal, M. Talpaz, and N.J. Donato Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells Clinical Cancer Research 19 2005 6924 6932
42. A.Z. Dudek, K. Lesniewski-Kmak, N.J. Shehadeh, O.N. Pandey, M. Franklin, and R.A. Kratzke Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor British Journal of Cancer 9 2009 1379 1384
43. J.R. Grandis, S.D. Drenning, Q. Zeng, S.C. Watkins, M.F. Melhem, and S. Endo Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo Proceedings of the National Academy of Sciences of the United States of America 97 8 2000 4227 4232